Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associa...
Jul 23, 2025, 7:00 AM EDT - 4 days ago
Jul 9, 2025, 7:00 AM EDT - 18 days ago
May 12, 2025, 7:18 PM EDT - 2 months ago
May 12, 2025, 4:01 PM EDT - 2 months ago
Apr 28, 2025, 7:00 AM EDT - 3 months ago
Apr 4, 2025, 4:05 PM EDT - 4 months ago
Mar 30, 2025, 4:00 PM EDT - 4 months ago
Mar 27, 2025, 5:45 AM EDT - 4 months ago
Mar 26, 2025, 2:19 AM EDT - 4 months ago
Mar 15, 2025, 9:29 AM EDT - 4 months ago
Mar 13, 2025, 10:19 AM EDT - 4 months ago
Mar 6, 2025, 12:17 PM EST - 5 months ago
Mar 4, 2025, 8:30 AM EST - 5 months ago
Mar 3, 2025, 11:37 AM EST - 5 months ago
Mar 3, 2025, 7:00 AM EST - 5 months ago
Feb 27, 2025, 5:45 AM EST - 5 months ago
Feb 26, 2025, 8:46 PM EST - 5 months ago
Feb 26, 2025, 1:32 PM EST - 5 months ago
Feb 20, 2025, 5:41 PM EST - 5 months ago
Feb 19, 2025, 10:08 PM EST - 5 months ago
Feb 13, 2025, 7:00 AM EST - 5 months ago